Saccharin Derivatives VIII. Hypotensive Agents

By GLENN H. HAMOR

Saccharin analogs of chlorothiazide have been reported to possess diuretic activity. This paper relates the synthesis of 6-chloro-2-methylsaccharin, which is structurally similar to 7-chloro-3-methyl-1,2,4-benzothiadiazine 1,1-dioxide (diazoxide), a nondiuretic, hypotensive benzothiadiazine. The 6-chloro-2-methylsaccharin along with some 9 related saccharin derivatives, which had been synthesized earlier in a continuing study of saccharin chemistry, were screened for pharmacological activity. Preliminary results indicate hypotensive effects in cats and dogs, with little diuretic response. In fact, 2-ethyl-4-nitrosaccharin showed antidiuretic properties. In addition to producing a moderate transient hypotension in the anesthetized dog, 6-chloro-2-methylsaccharin produced CNS stimulation in rats.

⁴HE DIURETIC activity of compounds related to 6chloro-7-sulfamoyl-1,2,4-benzothiadiazine 1.1dioxide (chlorothiazide) (I) is well known (1). Certain of them also show hypotensive activity and are used clinically in the treatment of mild hypertension (2). Several recent papers describe closely related substances lacking the sulfamoyl group, exemplified bv 7-chloro-3-methyl-1,2,4-benzothiadiazine 1,1dioxide (diazoxide) (II), as possessing antihypertensive but not diuretic activity (3-6).

The saccharin analogs, 5-chloro-6-sulfamoylsaccharin (III) (7) and 2-methyl-6-sulfamoylsaccharin (IV) (8), are reported to exhibit diuretic activity.1 This paper relates the results of preliminary pharmacological testing of some 9 saccharins corresponding to the hypotensive 1,2,4benzothiadiazines in not containing an extranuclear sulfamoyl group. The synthesis of 6-chloro-2methylsaccharin (V) is described. The remaining 8 saccharin derivatives had been prepared earlier in a continuing study of saccharin chemistry (9-11).

Because Topliss *et al.* (4) had reported most of the hypotensive activity of the benzothiadiazines to be retained if the chlorine at position 7 were replaced by nitro, various nitrosaccharins and related compounds were selected for testing (Table I). The 6chloro-2-methylsaccharin was synthesized by chlorosulfonation of 4-chlorotoluene, followed by treatment with aqueous ammonia, which gave 4-chlorotoluene-2-sulfonamide. Oxidation of this compound succeeded by a Williamson reaction of the resulting 6chlorosaccharin with methyl iodide gave the desired 6-chloro-2-methylsaccharin.

Preliminary pharmacological results² indicate these compounds to possess hypotensive effects, on intravenous injection in cats and dogs, of primarily a transient nature. The 4-nitro-2-n-propylsaccharin (compound 4) shows some evidence of autonomic ganglionic blocking. These substances possess little diuretic response. In fact, 2-ethyl-4-nitrosaccharin (compound 3) showed antidiuretic properties. In contrast, 2-methyl-6-sulfamoylsaccharin (IV), the diuretic compound, produced transient pressor effects in the cat after doses of 0.5-10.0 mg./Kg. intravenously. In addition to producing a moderate



transient hypotension following administration of 5 and 10 mg./Kg. i.v. in the dog, 6-chloro-2-methylsaccharin (V) caused CNS stimulation in rats orally at 300 mg./Kg. It may be of interest to note that this saccharin compound (V) is tasteless, as have been other N-substituted saccharins in our experience.

EXPERIMENTAL

6-Chloro-2-methylsaccharin (V).³-In a 200-ml. round-bottom flask fitted with a reflux condenser and heating mantle were placed 5.0 Gm. (0.023 mole) of 6-chlorosaecharin,⁴ m.p. 217° [reported m.p. 218° (12)], 1.3 Gm. (0.012 mole) of sodium carbonate, and 100 ml. of dimethylformamide. To this was added 7.3 Gm. (0.051 mole) of methyl iodide. The solution was refluxed for 1 hr. and then poured into approximtely 700 ml. of ice water. The mixture was cooled for 30 min., then filtered and washed with 2 portions of cold water to give 3.2 Gm. (60%) of white solid, m.p. 174-175.5°.5 Recrystallization

Received December 29, 1965, from the School of Pharmacy, University of Southern California, Los Angeles. Accepted for publication February 26, 1966. Presented to the (Pharmaceutical Sciences) Section (Np), American Association for the Advancement of Science, Ber-keley, Calif., meeting, December 1965. Previous paper: Hamor, G. H., J. Pharm. Sci., 52, 603 (1963)

^{(1963).}

¹ However, deStevens reports III to be inactive as a di-uretic. (See *Reference 1*, p. 113.) ² The author is indebted to Smith Kline & French Labora-

tories, Philadelphia, Pa., for pharmacological testing.

³ Chemical Abstracts nomenclature, 6-chloro-2-methyl-

 ^{4.2-}benzisothiazolin-3-one 1,1-dioxide.
 4 The author thanks Bernard L, Reavlin for synthesis of the sample of 6-chlorosaccharin.
 8 Melting points were determined by the open capillary tube method and are uncorrected.

TABLE 1.—SACCHARIN DERIVATIVES





 a Melting points were determined either with a Fisher-Johns melting point apparatus or by the capillary tube method and are uncorrected.

from acetone-water gave white needle crystals, m.p. 180-181°

Anal.6-Calcd. for C₈H₆ClNO₃S: C, 41.50; H, 2.61. Found: C, 41.60; H, 2.73.

REFERENCES

(1) deStevens, G., "Dirretive: Chemistry and Pharma-cology, Medicinal Chemistry," vol. 1, Academic Press Inc., New York, N. Y., 1963, p. 81.
 (2) Rubin, A. A., Roth, F. E., Taylor, R. M., and Rosen-kilde, H., J. Pharmacol. Expli. Therap., 136, 344(1962).
 (3) Rubin, A. A., Roth, F. E., Winbury, M. M., Topliss, J. G., Sherlock, M., Sperber, N., and Black, J., Science, 133, 9067(1961).

2067(1961).

⁶ Analyses were performed by Elek Microanalytical Laboratories, Torrance, Calif.

(4) Topliss, J. G., Sherlock, M. H., Reimann, H., Konzelman, L. M., Shapiro, E. P., Pettersen, B. W., Schneider, H., and Sperber, N., J. Med. Chem., 6, 122(1963).
(5) Topliss, J. G., Konzelman, L. M., Shapiro, E. P., Sperber, N., and Roth, F. E., *ibid.*, 7, 269(1964).
(6) Bierbaum, B. A., Traverso, J. J., and Whitchead, C. W., *ibid.*, 6, 272(1963).
(7) Novello, F. C., "Edema," Moyer, J. H., and Fuchs, M., eds., W. B. Saunders Co., Philadelphia, Pa., 1960, p. 269.
(8) Hamor, G. H., J. Pharm. Sci., 51, 1109(1962).
(9) Hamor, G. H., and Soine, T. O., J. Am. Pharm. Assoc., Sci. Ed., 43, 120(1954).
(10) Hamor, G. H., ind Hamor, G. H., J. Pharm. Sci., 50, 672(1961).

- (11) Menta, S. J., and Hamor, G. H., J. T. as in Con-672(1961).
 (12) De Roode, R., Am. Chem. J., 13, 217(1891).
 (13) Noyes, W. A., *ibid.*, 8, 167(1886).
 (14) Hamor, G. H., unpublished data.
 (15) Abe, K., J. Pharm. Soc. (Japan), 75, 153(1955).

Thin-Layer Chromatography of Cardiac Glycosides

By EUGENE J. JOHNSTON and ALLEN L. JACOBS

A rapid thin-layer chromatographic procedure for the separation and identification of the common cardiac glycosides is presented. A benzene-ethanol solvent is used for development and a perchloric acid spray for visualization.

⁴HIN-LAVER chromatography has proven to be more rapid and sensitive than paper chromatography for the identification and purity determination of many drugs. A number of solvent systems and sprays useful for cardiac glycosides have been published (1-4). This paper reports the development of a relatively simple technique which has certain advantages over these approaches.

EXPERIMENTAL

Thin-Layer Plates .- A 0.25-mm. layer of Silica Gel G (E. Merck, Darmstadt) is applied to the plates. The plates are air dried for 10 min., then heated in an oven for 45 min. at 120°. The plates are stored in a desiccator and used without further activation.

Solvent System.—Benzene-95% ethanol (7:3 v/v).

Spray Reagent.-Fifteen milliliters of 70% perchloric acid added to 100 ml. of water.

Preparation of Samples.-The substances are dissolved in a suitable solvent, usually methanol. For purity studies, 100 mcg. of substance is spotted on

Received January 10, 1966, from the Analytical Research Department, Sandoz Pharmaceuticals, Hanover, N. J. Accepted for publication February 21, 1966.